How to Get Repatha (Evolocumab) in Michigan

What Is Repatha and Why Is It Prescribed?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab increases the number of functional LDL receptors, which lowers circulating LDL-cholesterol by 55 to 75 percent on top of background statin therapy [1]. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C reduction [2].

The landmark FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every 2 weeks or 420 mg monthly reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15 percent relative to placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years of follow-up [3]. Mean LDL-C fell from 92 mg/dL at baseline to 30 mg/dL on evolocumab, a 59 percent reduction [3]. That trial enrolled patients already on optimized statin therapy, which is exactly the clinical context Michigan insurers expect before approving a Repatha prescription.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy with LDL-C levels persistently 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor." [4] Michigan prescribers and payers use that threshold routinely when evaluating eligibility.

Who Can Prescribe Repatha in Michigan?

Any Michigan-licensed prescriber with authority to prescribe Schedule III-V and non-controlled prescription drugs may write for evolocumab. That includes MDs, DOs, NPs (nurse practitioners), and PAs (physician assistants) practicing within their scope. Michigan NPs hold full practice authority under MCL 333.17210, meaning they do not need a physician cosignature to prescribe Repatha independently [5]. PAs prescribe under a practice agreement with a supervising physician, but that agreement routinely covers lipid-lowering biologics.

Specialists who commonly prescribe evolocumab in Michigan include preventive cardiologists, lipidologists, endocrinologists, and internists. Primary care physicians and NPs at family medicine or internal medicine practices prescribe it too, particularly for patients with established ASCVD who are already in their panel. The Michigan Department of Licensing and Regulatory Affairs (LARA) maintains the license verification portal at lara.michigan.gov, where patients can confirm a prescriber's active status before scheduling [6].

For telehealth visits, the prescriber must hold an active Michigan license. Michigan law does not require an initial in-person visit before a telehealth provider prescribes a non-controlled medication, so a video or asynchronous visit is legally sufficient to initiate a Repatha prescription [7].

What Labs Do You Need Before Getting a Repatha Prescription in Michigan?

Before any prescriber in Michigan writes for evolocumab, they will want a recent fasting lipid panel, typically obtained within the past 3 to 6 months. A fasting lipid panel includes total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides. If triglycerides exceed 400 mg/dL, a direct LDL-C measurement is preferred over the Friedewald equation [8].

The standard pre-prescription lab workup includes:

1. Fasting lipid panel to document baseline LDL-C and confirm it exceeds the prior-authorization threshold (typically 70 mg/dL for ASCVD or 100 mg/dL for HeFH without ASCVD).
2. Liver function tests (AST, ALT) to rule out active hepatic disease, which is a clinical contraindication.
3. Creatine kinase (CK) if the patient reports myalgia on statin therapy, since statin-associated muscle symptoms are among the most common reasons patients cannot reach goal on statins alone.
4. TSH to exclude hypothyroidism as a secondary cause of hypercholesterolemia.
5. HbA1c or fasting glucose because familial hypercholesterolemia often coexists with metabolic syndrome.

Some Michigan telehealth platforms partner with local draw sites such as LabCorp or Quest Diagnostics, allowing patients to complete labs before their video visit so the prescriber can review results in real time [9]. The ACC/AHA Familial Hypercholesterolemia Task Force recommends cascade screening with a fasting lipid panel for first-degree relatives of any confirmed FH patient, which means a Michigan patient newly diagnosed with HeFH may prompt testing of family members as well [10].

How to Get a Repatha Prescription in Michigan: Step-by-Step

Getting evolocumab in Michigan follows a predictable sequence regardless of whether the visit is in-person or via telehealth.

Step 1. Confirm clinical eligibility. Your LDL-C must exceed the payer threshold despite maximally tolerated statin therapy. "Maximally tolerated" means the highest dose the patient can take without intolerable side effects, not necessarily the maximum labeled dose. Patients with documented statin intolerance may qualify with a lower or no statin dose if they have tried at least two different statins [11].

Step 2. Gather prior medication history. Collect records showing at least one, and preferably two, statin trials with doses and durations. Payers in Michigan also want documentation of any additional lipid-lowering agents tried, such as ezetimibe 10 mg daily, which costs under $10/month generic and is almost always required before PCSK9 inhibitor approval [12].

Step 3. Schedule a prescriber visit. This may be in-person at a Michigan cardiology or lipid clinic, or via a licensed Michigan telehealth service. Bring your lab results, medication list, and prior EOB or pharmacy printouts showing statin history.

Step 4. Receive the prescription and submit to specialty pharmacy. Repatha is a specialty-tier biologic. Most Michigan retail pharmacies do not stock it. The prescriber or the prescriber's office typically sends the prescription directly to a contracted specialty pharmacy such as Walgreens Specialty, CVS Specialty, or Accredo [13].

Step 5. Manage prior authorization. The specialty pharmacy or the prescriber's office initiates the PA request on your behalf. See the prior authorization section below for what Michigan payers require.

Step 6. Access patient assistance if needed. Amgen's Repatha patient assistance program, Repatha SupportPlus, may cover out-of-pocket costs for eligible commercially insured patients. For Michigan Medicaid beneficiaries, the standard copay assistance programs do not apply, but Medicaid's own cost-sharing is typically low once PA is approved [14].

Prior Authorization for Repatha in Michigan: What Payers Require

Prior authorization is the single biggest barrier to getting Repatha in Michigan. Every major Michigan commercial insurer, including Blue Cross Blue Shield of Michigan, Priority Health, and Molina Michigan, requires PA for evolocumab. Michigan Medicaid (Healthy Michigan Plan) also requires PA but does cover the drug for qualifying diagnoses [15].

A typical Michigan PA request for evolocumab must document:

• Diagnosis code. ICD-10 E78.01 (HeFH), E78.02 (HoFH), or I25.10 (ASCVD, chronic ischemic heart disease) are the most accepted codes.
• Current LDL-C value with date. Most payers want LDL-C at or above 70 mg/dL for ASCVD or 100 mg/dL for FH, obtained within 90 days.
• Statin trial documentation. At minimum, one moderate-to-high-intensity statin at the maximally tolerated dose for 8 to 12 weeks. High-intensity statins include atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg daily [16].
• Ezetimibe trial. Most Michigan payers require ezetimibe 10 mg daily to have been tried for at least 4 to 8 weeks unless there is a documented contraindication.
• Reason for inadequate response or intolerance. Lab values or physician notes documenting why lower-tier therapy failed.

Blue Cross Blue Shield of Michigan's clinical criteria, last updated in 2024, require that PCSK9 inhibitors be prescribed by or in consultation with a cardiologist or lipid specialist for most ASCVD indications, though a primary care prescriber may qualify if they document the specialist consultation in the chart [17].

The HealthRX Prior Authorization Readiness Checklist for Michigan Repatha requests consolidates these requirements. Before submitting a PA, confirm all five elements are present: (1) qualifying ICD-10 code in the chart, (2) LDL-C above the threshold dated within 90 days, (3) two statin trials documented by name and dose, (4) ezetimibe trial documented, and (5) prescriber specialty or specialist note in the file. Missing any one of these is the most common reason for an initial denial in Michigan.

PA approval timelines in Michigan average 7 to 14 calendar days for standard reviews and 72 hours for urgent or expedited reviews under Michigan's utilization review statute, MCL 550.1901 et seq [18]. An appeal is available within 60 days of a denial, and patients have the right to request an external independent review through the Michigan Department of Insurance and Financial Services (DIFS) if the internal appeal fails [18].

Telehealth Options for Getting Repatha in Michigan

Michigan is one of the states where telehealth prescribing of non-controlled specialty medications is fully permitted without a prior in-person visit. A Michigan-licensed prescriber conducting a synchronous video visit or, for established patients, an asynchronous encounter may legally initiate and refill a Repatha prescription [7].

Telehealth platforms serving Michigan patients for lipid management typically offer:

• A video visit with an MD, DO, NP, or PA licensed in Michigan.
• In-house ordering of fasting lipid panels through a partner laboratory network, with results available before or during the visit.
• Direct submission of the Repatha prescription to a contracted specialty pharmacy.
• Prior authorization support staff who handle the PA paperwork, including peer-to-peer calls with insurer medical directors if an initial denial occurs.

Asynchronous telehealth, where the patient completes a detailed intake questionnaire and the provider reviews it later, may be used for refills once the prescribing relationship is established. Michigan law requires synchronous (real-time audio-visual) contact for new prescriptions of biologics under most major payer contracts, even if state law is more permissive [19]. Patients should confirm this with their specific insurer before booking an asynchronous-only encounter.

Average wait times for a new telehealth lipid consultation in Michigan run 2 to 5 business days for appointment scheduling, after which the PA process begins. Total time from first telehealth visit to first injection is typically 14 to 21 days when labs are already available and the clinical record is complete [20].

Repatha Pharmacy Access in Michigan

Repatha is distributed exclusively through specialty pharmacies. Michigan patients cannot walk into a standard retail pharmacy and pick up evolocumab off the shelf. Contracted specialty pharmacies that service Michigan include:

• Walgreens Specialty Pharmacy (ships to Michigan home addresses)
• CVS Specialty (mail-order and some Michigan specialty locations)
• Accredo (Express Scripts specialty division, ships statewide)
• Optum Specialty Pharmacy (ships statewide, services most BCBSM plans)
• Amber Specialty Pharmacy (regional Midwest specialty pharmacy with Michigan service)

Evolocumab requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) during storage [2]. Specialty pharmacies ship it with cold packs and temperature monitors. Patients may store it at room temperature, up to 77 degrees Fahrenheit (25 degrees Celsius), for up to 30 days in the original carton without degradation [2]. Once removed from refrigeration, the 30-day clock is irreversible.

Regarding 503A compounding pharmacies in Michigan: evolocumab is a large-molecule biologic (monoclonal antibody), which means it cannot be compounded by a 503A pharmacy in any clinically meaningful way. The FDA has not listed evolocumab on any 503A bulk drug substance list, and compounding a monoclonal antibody requires bioreactor manufacturing infrastructure that no 503A pharmacy possesses [21]. Any offer of "compounded evolocumab" from a Michigan or out-of-state pharmacy should be treated as a red flag. The branded Repatha product from Amgen is the only legally available form.

Pricing without insurance runs approximately $600 to $700 per monthly dose (SureQty 420 mg autoinjector) or $550 to $650 per biweekly dose (140 mg autoinjector) at Michigan specialty pharmacies. The Amgen SupportPlus copay card may reduce commercial plan cost-sharing to as little as $0 per month for eligible patients earning above Medicaid thresholds [22].

Transferring an Existing Repatha Prescription to Michigan

Patients moving to Michigan from another state with an active evolocumab prescription can transfer it under the following conditions. The prescriber who wrote the original prescription must hold or obtain a Michigan license, or the patient must establish care with a new Michigan-licensed prescriber. Specialty pharmacies operate federally regulated distribution networks, so Accredo or CVS Specialty can update a patient's shipping address to a Michigan location without requiring a new prescription if the prescriber is already Michigan-licensed [23].

For patients whose prior prescriber is not licensed in Michigan, the transfer process requires a new clinical encounter. The new Michigan prescriber will want the most recent lipid panel, the original prescription history, and any PA approval letters from the prior payer to expedite the re-authorization process with the Michigan insurer.

Michigan Medicaid (Healthy Michigan Plan) does not recognize prior authorizations granted by another state's Medicaid program. A new PA must be filed with the Michigan Medicaid managed care organization (MCO) the patient is enrolled in. Michigan Medicaid MCOs include Molina Healthcare of Michigan, Priority Health Government, and Blue Cross Complete, among others [24].

Cost Assistance and Michigan Medicaid Coverage

Michigan Medicaid covers evolocumab for HeFH and established ASCVD with prior authorization. The Michigan Medicaid PDL (Preferred Drug List) places evolocumab in a non-preferred specialty tier, meaning PA is required but approval is achievable with adequate clinical documentation [15]. Michigan Medicaid PA criteria mirror the commercial criteria closely: documented LDL-C above threshold, statin trial, and ezetimibe trial.

For uninsured Michigan residents, Amgen's patient assistance program provides Repatha at no cost to patients with household incomes at or below 600 percent of the federal poverty level who meet clinical criteria [14]. The application is submitted by the prescribing provider, not the patient, and approval typically takes 10 to 15 business days.

The PCSK9 inhibitor class as a whole has moved toward greater access since 2020, partly due to price reductions negotiated through pharmacy benefit managers. The Institute for Clinical and Economic Review (ICER) estimated in 2020 that a 40 to 65 percent reduction in list price would bring evolocumab to cost-effectiveness thresholds of $100,000 to $150,000 per QALY [25]. Amgen's net price after rebates has declined substantially from the 2015 launch price of approximately $14,100 per year, though the exact net price varies by payer contract [22].

Safety, Monitoring, and Follow-Up After Starting Repatha in Michigan

Evolocumab has a favorable safety profile documented across the FOURIER trial and the open-label OSLER-1 and OSLER-2 extension studies (combined N=4,465, median follow-up 11.1 months) [26]. The most common adverse events are injection-site reactions (occurring in 3.2 percent of evolocumab-treated patients vs. 3.0 percent of placebo) and nasopharyngitis [26]. No clinically meaningful increase in hepatotoxicity, myopathy, or new-onset diabetes was observed in those trials [3].

After starting evolocumab, Michigan providers typically follow this monitoring schedule:

• 4 to 8 weeks post-initiation: Repeat fasting lipid panel to confirm LDL-C response. A less than 30 percent reduction should prompt a review of injection technique and adherence.
• Every 3 to 6 months for the first year: Lipid panel and clinical assessment.
• Annually thereafter: Lipid panel, review of cardiovascular risk factors, and assessment of ongoing PA renewal requirements. Most Michigan payers require annual PA renewal with updated lipid values.

The 2018 AHA/ACC Multi-Society guideline recommends that clinicians aim for an LDL-C below 55 mg/dL in very-high-risk ASCVD patients, a threshold achievable with evolocumab in most patients when added to high-intensity statin therapy [27].